NCT04219254: A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least 2 doses of an approved anti-PD-1/L1 monoclonal antibody, & have documented progression on or within 12 weeks from the last dose of anti-PD-1/L1 treatment
Exclusions: Patients with known active central nervous system (CNS) metastases and/or leptomeningeal disease

Comments are closed.

Up ↑